Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection
NCT04899336Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2021
- Primary completion
- Aug 2025
- Modality
- Split/Subunit Vaccines
- Countries
- 21
01
Overview
A Phase 3 trial of ExPEC9V in invasive extraintestinal pathogenic Escherichia coli disease (IED), sponsored by Janssen Pharmaceutical. Started Jun 2021; status: completed.
02
Drugs
ExPEC9V
03
Conditions
invasive extraintestinal pathogenic Escherichia coli disease (IED)
Beyond the preview
Go deeper on NCT04899336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04899336.